CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 19 enrolled
Drug / intervention
Vismodegib +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00959647
NCT00959647Phase 2Completed
CompareCT.gov

An Open-Label, Multicenter Extension Study of GDC-0449 (Hedgehog Pathway Inhibitor) in Patients Treated With GDC-0449 in a Previous Genentech-sponsored Phase I or Phase II Cancer Study

Genentech, Inc.·interventional·Posted Aug 14, 2009·Updated May 8, 2026

In Brief

A Phase 2 clinical trial evaluating Vismodegib, FOLFOX, and 2 other interventions for Ovarian Cancer and 2 related conditions. Completed, enrolled 19 participants across 10 sites.

Detailed Summary

This was a multicenter, open-label extension study. Patients who received vismodegib (GDC-0449) in a Genentech-sponsored study and who had completed the parent study or who continued to receive vismodegib at the time the parent study closed were eligible for continued treatment in this protocol.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOvarian Cancer, Basal Cell Carcinoma, Metastatic Colorectal Cancer
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedAug 14, 2009
Enrollment StartSep 3, 2009
Primary CompletionJan 9, 2014
TodayJul 2, 2026
Enrollment to primary: 4.4 yearsPosted 16.9 years ago

Interventions

Vismodegibdrug

Vismodegib was supplied in capsules.

FOLFOXdrug

FOLFOX (folinic acid \[FOL, leucovorin\], fluorouracil \[F, 5-FU\], and oxaliplatin \[OX\]) was supplied as solutions for intravenous administration.

FOLFIRIdrug

FOLFIRI (folinic acid \[FOL, leucovorin\], fluorouracil \[F, 5-FU\], and irinotecan \[IRI\]) was supplied as solutions for intravenous administration.

Bevacizumabdrug

Bevacizumab was supplied as a solution for intravenous administration.